Effects of DPP4 inhibitor, sitagliptin or Sulfonylurea on intrahepatic adipose mass and lipid metabolism in patients with type 2 diabetes accompanied by fatty liver : a prospective randomized, open-label trial
Not Applicable
Completed
- Conditions
- Type 2 diabetes
- Registration Number
- JPRN-UMIN000013356
- Lead Sponsor
- St.Marianna University School of Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 60
Inclusion Criteria
Not provided
Exclusion Criteria
1)Patients who had diabetic ketosis, or diabetic pre-coma and coma within 6 months of the study entry. 2)Patients with severe infections, before or after operation, or with serious trauma. 3)Patients with pregnancy, possibility of pregnancy or having a breast feeding. 4)Patients with renal insufficiency (serum creatinine = and > 1.5 mg/dl) 5)Patients who received insulin therapy. 6)Patients who administered antihyperlipidemic agent other than Metformin for observation period. 7)Patients who had a history of hypersensitive reaction to DPP-4 inhibitor. 8)Patients whom the attending doctor estimated to be ineligible according to the medical rationale.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method amount of Intrahepatic adipose mass and visceral fat(MRI,DEXA)
- Secondary Outcome Measures
Name Time Method